Friday, December 4, 2020

COVID-19: Zydus Cadila gets DGCI nod for phase 3 clinical trials with biological therapy

COVID-19: Zydus Cadila gets DGCI nod for phase 3 clinical trials with biological therapy In a regulatory filing, Zydus Cadila said it has received approval from the DCGI to start the phase 3 clinical trials in COVID-19 patients with its biological therapy Pegylated Interferon alpha-2b or PegiHep.

from Moneycontrol Business News https://ift.tt/2JAEliD
Labels:

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)

FII exodus deepens in 2026 at Rs 1.75 lakh crore as April outflows swell to Rs 43,967 crore; FOMC next trigger

Foreign institutional investors offloaded Indian equities worth Rs 17,140 crore last week, extending April's outflows to Rs 43,967 crore...